This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khosla, S. Articles by Orwoll, E. Search for Related Content PubMed PubMed Citation Articles by Khosla, S. Articles by Orwoll, E.

Osteoporosis in Men

Endocrine Research Unit (S.K.) and Division of Rheumatology (S.A.), College of Medicine, Mayo Clinic, Rochester, Minnesota 55905; and Division of Endocrinology (E.O.), Oregon Health & Science University, Portland, Oregon 97201

Correspondence: Address all correspondence and requests for reprints to: Sundeep Khosla, M.D., Guggenheim 7, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905; khosla.sundeep{at}mayo.edu

With the aging of the population, there is a growing recognition that osteoporosis and fractures in men are a significant public health problem, and both hip and vertebral fractures are associated with increased morbidity and mortality in men. Osteoporosis in men is a heterogeneous clinical entity: whereas most men experience bone loss with aging, some men develop osteoporosis at a relatively young age, often for unexplained reasons (idiopathic osteoporosis). Declining sex steroid levels and other hormonal changes likely contribute to age-related bone loss, as do impairments in osteoblast number and/or activity. Secondary causes of osteoporosis also play a significant role in pathogenesis. Although there is ongoing controversy regarding whether osteoporosis in men should be diagnosed based on female- or male-specific reference ranges (because some evidence indicates that the risk of fracture is similar in women and men for a given level of bone mineral density), a diagnosis of osteoporosis in men is generally made based on male-specific reference ranges. Treatment consists both of nonpharmacological (lifestyle factors, calcium and vitamin D supplementation) and pharmacological (most commonly bisphosphonates or PTH) approaches, with efficacy similar to that seen in women. Increasing awareness of osteoporosis in men among physicians and the lay public is critical for the prevention of fractures in our aging male population.

This article has been cited by other articles:

				S. Khosla Update in Male Osteoporosis J. Clin. Endocrinol. Metab., January 1, 2010; 95(1): 3 - 10. [Abstract] [Full Text] [PDF]

				S. Khosla Testosterone: More Is Not Always Better J. Clin. Endocrinol. Metab., December 1, 2009; 94(12): 4665 - 4667. [Full Text] [PDF]

				B. Z. Leder, R. M. Neer, J. J. Wyland, H. W. Lee, S.-A. M. Burnett-Bowie, and J. S. Finkelstein Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with Osteoporosis J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2915 - 2921. [Abstract] [Full Text] [PDF]

				I. Tatsuno, T. Sugiyama, S. Suzuki, T. Yoshida, T. Tanaka, M. Sueishi, and Y. Saito Age Dependence of Early Symptomatic Vertebral Fracture with High-Dose Glucocorticoid Treatment for Collagen Vascular Diseases J. Clin. Endocrinol. Metab., May 1, 2009; 94(5): 1671 - 1677. [Abstract] [Full Text] [PDF]

				F. Callewaert, K. Venken, J. Ophoff, K. De Gendt, A. Torcasio, G. H. van Lenthe, H. Van Oosterwyck, S. Boonen, R. Bouillon, G. Verhoeven, et al. Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor-{alpha} FASEB J, January 1, 2009; 23(1): 232 - 240. [Abstract] [Full Text] [PDF]